country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-183185

Copy Link Print Information

BZ-30

BZ-30 is an orally active broad-spectrum SARS-CoV-2 inhibitor. BZ-30 acts on the early stage of the viral life cycle, can partially inhibit the endosomal entry process and reduce viral replication levels. BZ-30 reduces viral load, improves pulmonary pathological conditions, and decreases the lung-to-body weight ratio in hamster models challenged with SARS-CoV-2. BZ-30 can be used for research related to COVID-19.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 3028405-31-1
Formel: C₁₄H₁₃F₆N₃
Molecular Weight:337.26

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

BZ-30 Chemical Structure

CAS. Nr.: 3028405-31-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

BZ-30 (0.15-5 μM) reduces viral RNA levels by ≥99% in wild-type SARS-CoV-2-infected Vero E6 cells at the concentration of 5 μM, and exhibits dose-dependent antiviral activity^[1].
BZ-30 (24 h) potently inhibits the effective replication of wild-type SARS-CoV-2 in Vero E6 cells, with an IC₅₀ of 0.65 μM^[1].
BZ-30 (24 h) acts as a broad-spectrum inhibitor of SARS-CoV-2 variants of concern in Vero E6 cells, with IC₅₀ values ranging from 0.51 μM (Beta variant) to 12.37 μM (Omicron variant)^[1].
BZ-30 can partially inhibit the endosomal entry of SARS-CoV-2 pseudovirus; its inhibitory effect is stronger in HEK293-ACE2 cells (up to 75%) compared with the 50% inhibition rate observed in HEK293-ACE2/TMPRSS2 cells^[1].
BZ-30 (0-24 h) acts on the early stage of the wild-type SARS-CoV-2 life cycle in Vero E6 cells, and inhibits viral replication when administered within 2 h post-infection^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	T_max	C_max	AUC_0-last	AUC_0-∞	Bioavailability	T_1/2	V_d	CL
Mice^[1]	5 mg/kg	i.v.	/	/	711.9 nM·h	877.6 nM·h	/	3.9 h	8.43 L/kg	1.89 L/h/kg
Mice^[1]	10 mg/kg	p.o.	0.5 h	5003.8 nM	1759.4 nM·h	3029.1 nM·h	100 %	/	/	/

In Vivo

BZ-30 (15 mg/kg; i.p.; twice daily; 4 days starting 8 hours post-infection) reduces SARS-CoV-2 viral load by 64% and improves lung pathology in SARS-CoV-2-challenged Syrian golden hamsters^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Syrian Golden Hamsters (female, 6-8 weeks old, intranasally inoculated with 10⁵ PFU of SARS-CoV-2)^[1]
Dosage:

15 mg/kg
Administration:

i.p.; twice daily; 4 days (starting 8 h post-infection)
Result:

Reduced viral load by log₁₀ 0.44 TCID₅₀ per mg lung, corresponding to a 64% reduction in viral load.
Significantly reduced the lung-to-body weight ratio.
Maintained body weight comparable to the positive control remdesivir.
Lowered the cumulative histopathological lung score from 14 to 3.
Showed minimal alveolar and epithelial cell degeneration, with only occasional peri-vascular and peri-bronchiolar focal inflammatory cell infiltration.

Chemical Information

CAS. Nr. 3028405-31-1
Molecular Weight 337.26
Formel C₁₄H₁₃F₆N₃
SMILES

CC1(CCC1)NC2=NC3=C(C(F)(F)F)C=C(C(F)(F)F)C=C3N2
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Kaur S, et al. Development of Benzimidazole-Based BZ-30 as an Orally Bioavailable Broad-Spectrum Inhibitor of SARS-CoV-2. J Med Chem. 2026;69(8):9537-9557. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen